Buyer Class Fights Allergan Over Causation In Antitrust Row

Law360, New York (December 5, 2017, 1:28 PM EST) -- A class of end purchasers accusing Allergan PLC and its subsidiary Warner Chilcott Ltd. of stifling competition for their ulcerative colitis drugs urged a Massachusetts federal court Monday not to certify a causation issue, saying they’ve adequately argued that the companies’ alleged wrongdoing caused them harm.

The end purchasers said they sufficiently alleged Warner Chilcott's “hard switch” from Asacol, which had patents nearing expiration, to newer drugs without generic alternatives caused them harm because Asacol was likely to face generic competition even if there were no...
To view the full article, register now.